| Id: | acc3012 |
| Group: | 1sens_supp |
| Protein: | Akt |
| Gene Symbol: | Akt1 |
| Protein Id: | P31750 |
| Protein Name: | AKT1_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser473 |
| Site Sequence: | ERRPHFPQFSYSASGTA---- |
| Disease Category: | Cardiovascular and circulatory system diseases |
| Disease: | Myocardial Infarction |
| Disease Subtype: | diabetes mellitus |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | rapamycin(RAPA) |
| Drug Info: | Rapamycin (RAPA) is a well - known immunosuppressant and autophagy inducer that has various applications in medical research and treatment. |
| Effect: | modulate |
| Effect Info: | "After I/R injury, RAPA restored the phosphorylation of AKT (a target of mTORC2) but inhibited the phosphorylation of S6 (a target of mTORC1)." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 31738412 |
| Sentence Index: | 31738412_15_supp |
| Sentence: | "RAPA-induced cardioprotection against I/R injury as well as the induction of miR-17/20a and AKT phosphorylation were abolished in cardiac-specific STAT3-deficient diabetic mice, without alteration of S6 phosphorylation. The infarct-limiting effect of RAPA was obliterated in cardiac-specific miRNA-17-92-deficient diabetic mice. The post-I/R restoration of phosphorylation of STAT3 and AKT with RAPA were also abolished in miRNA-17-92-deficient diabetic mice." |
Sequence & Structure:
MNDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQRESPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWATAIQTVADGLKRQEEETMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPTQRLGGGSEDAKEIMQHRFFANIVWQDVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 473 | D | Alzheimer's disease | Phosphorylation | 35834993 ; 36843923 |
| S | 473 | D | Colonic inflammation | Phosphorylation | 36735734 |
| S | 473 | D | Diabetes mellitus | Phosphorylation | 17130464 ; 16777975 ; 15033922 ; 15033922 ; 16777975 ; 17130464 ; 35739993 |
| S | 473 | D | Turner syndrome | Phosphorylation | 33910978 |
| S | 473 | U | Cardiomyopathy | Phosphorylation | 35358489 |
| S | 473 | U | Diabetes mellitus | Phosphorylation | 35358489 |
| S | 473 | U | Endometrial cancer/carcinoma | Phosphorylation | 16585156 |
| S | 473 | U | Melanoma | Phosphorylation | 26565903 |
| S | 473 | U | Non-small cell lung cancer | Phosphorylation | 35961388 |
| S | 473 | U | Hepatocellular carcinoma | Phosphorylation | 33500384 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
